[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571856":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":29,"responsibleParty":46,"collaborators":50,"id":52,"slug":10,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":10,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":64,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":72,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Tianjin Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single Group Assignment",null,"Each subject receive a single intravenous injection of 68Ga\u002F18F-Exendin 4, and undergo PET\u002FCT imaging within the specificed time.",[13],"Diagnostic Test: 18F\u002F68Ga-Exendin 4",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","18F\u002F68Ga-Exendin 4",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Qiusong Chen, MD","CONTACT","+862260362190","qs_c8@hotmail.com",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"Haonan Yu, MD","+8613821000597","dreamadam@126.com",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Tianjin Medical University General Hospital","RECRUITING","Tianjin","Tianjin Municipality","300052","China","CN",{"type":39,"coordinates":40},"Point",[41,42],117.17667,39.14222,{"lat":42,"lon":41},[45],{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Shaobo Yao, PhD","Prof.",[51],{"name":31,"class":6},"100571856",false,"NCT06725693","Glucagon-like Peptide-1 Receptor PET\u002FCT in GLP-1R Related Disease","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Exendin 4 PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",true,"ALL","18 Years","80 Years",{"count":62,"type":63},500,"ESTIMATED","7 Days","OBSERVATIONAL","To evaluate the potential usefulness of 68Ga\u002F18F-Exendin 4 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various GLP-1R-related disease patients.",[68,69,70,71],"GLP1-R-related Disease","Tumor","Insulinoma","Positron Emission Tomography",[73,74],"PET\u002FCT","GLP1-R","2025-02-07",{"date":77,"type":78},"2025-02-11","ACTUAL",{"date":80,"type":78},"2019-02-01",{"date":82,"type":63},"2027-11-01",{"name":5,"class":6},1]